Mesothelioma / MESO (TCGA)

Overview

MESO is the TCGA cohort identifier for mesothelioma (predominantly pleural). The closest OncoTree equivalent is PLMESO (Pleural Mesothelioma). Mesothelioma is strongly associated with prior asbestos exposure and is characterized by BAP1, NF2, and CDKN2A/B alterations.

Cohorts in the corpus

• TCGA MESO cohort: included as one of 33 cancer types in the pan-cancer fusion landscape study; subset of the PanCancer Atlas (meso_tcga_pan_can_atlas_2018).

Recurrent alterations

• Pan-cancer fusion study (9,624 TCGA samples) included MESO as one of 33 cancer types; kinase-partner fusion over-expression outliers ranged from 6% (MESO, lowest) to 28% (KIRP), indicating MESO has the lowest rate of kinase-fusion-driven overexpression PMID:29617662.

Subtypes

• Epithelioid (better prognosis), sarcomatoid, and biphasic histologic subtypes are recognized; TCGA MESO cohort contains predominantly epithelioid tumors.

Therapeutic landscape

No drug-specific findings for MESO reported in the current corpus.

Sources

• PMID:29617662 — Pan-cancer fusion landscape (Gao et al., 2018)

This page was processed by crosslinker on 2026-05-15.